42 studies found for:    "Insulinoma"
Show Display Options
Rank Status Study
21 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
22 Completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study
23 Completed
Has Results
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Multiple Endocrine Neoplasia Type 1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
24 Terminated
Has Results
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Condition: Pancreatic Cancer
Interventions: Drug: Bortezomib;   Drug: Panobinostat
25 Active, not recruiting Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Metastatic Cancer
Intervention: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
26 Completed Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Interventions: Drug: capecitabine;   Drug: cisplatin;   Drug: streptozocin;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: protein analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis
27 Completed
Has Results
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Condition: Cancer
Interventions: Drug: Fentanyl sublingual spray;   Drug: Placebo
28 Terminated Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Conditions: Head and Neck Cancer;   Islet Cell Tumor;   Metastatic Cancer;   Pheochromocytoma
Interventions: Drug: octreotide acetate;   Radiation: yttrium Y 90 resin microspheres
29 Unknown  Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Metastatic Cancer;   Neoplastic Syndrome
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment
30 Completed
Has Results
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: AMG 706;   Drug: octreotide
31 Completed Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
32 Completed Cinacalcet to Treat Familial Primary Hyperparathyroidism
Conditions: Hypercalcemia;   Familial Primary Hyperparathyroidism
Interventions: Procedure: Parathyroid hormone testing;   Procedure: Serum calcium testing
33 Withdrawn Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Interventions: Drug: octreotide acetate;   Drug: vatalanib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological therapy;   Procedure: endocrine therapy;   Procedure: enzyme inhibitor therapy;   Procedure: growth factor antagonist therapy;   Procedure: hormone therapy;   Procedure: protein tyrosine kinase inhibitor therapy;   Procedure: somatostatin analogue therapy
34 Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome;   Neuroendocrine Tumor
Interventions: Biological: bevacizumab;   Drug: 5-fluorouracil;   Drug: leucovorin;   Drug: oxaliplatin
35 Completed Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Condition: Cancer
Interventions: Drug: isolated perfusion;   Drug: melphalan
36 Completed Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: 90Y-DOTA-tyr3-OCTREOTIDE
37 Completed Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome
Intervention: Drug: thalidomide
38 Completed PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Intervention: Drug: bortezomib
39 Completed Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Conditions: Brain and Central Nervous System Tumors;   Breast Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Lymphoma;   Melanoma (Skin);   Neoplastic Syndrome
Intervention: Radiation: yttrium Y 90-edotreotide
40 Completed Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
Condition: Cancer
Interventions: Drug: floxuridine;   Drug: leucovorin calcium;   Drug: oxaliplatin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-42) Show next page of results    Last Page
Indicates status has not been verified in more than two years